STAT3 and hepatocellular carcinoma: Evidence has confirmed that sorafenib acts on the Ras/Raf/MEK/ERK and JAK/STAT3 pathways through tyrosine kinase receptors, inhibiting angiogenesis, cell growth, and metastasis of HCC [402, 403], successfully extending the overall median survival in patients with advanced HCC [404].